HEALTHCARE INSTITUTE OF NEW JERSEY

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information (in the previous Congress, H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the ORPHAN CURES Act (H.R. 946). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761.